Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
Fiche publication
Date publication
mars 2018
Journal
European journal of gastroenterology & hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
Tous les auteurs :
Roulot D, Thibault V, Laforest C, Fontaine H, Bronowicki JP, Asselah T, Bourlière M, Canva V, Leroy V, Loustaud-Ratti V, Ouzan D, Zoulim F, Schischmanoff O, Rousseau C, Renault A, Petrov-Sanchez V, Diallo A, Bellissant E, Serfaty L,
Lien Pubmed
Résumé
A few direct antiviral agents have been studied in difficult-to-treat patients infected by hepatitis C virus (HCV) genotype 4 (GT4). The efficacy of daclatasvir (DCV), asunaprevir (ASV), pegylated interferon and ribavirin (Peg-IFN/RBV) association was investigated in these patients.
Mots clés
Adult, Antiviral Agents, adverse effects, Drug Therapy, Combination, Female, Genotype, Hepacivirus, classification, Hepatitis C, Chronic, complications, Humans, Imidazoles, adverse effects, Interferon alpha-2, Interferon-alpha, adverse effects, Isoquinolines, adverse effects, Liver Cirrhosis, virology, Male, Middle Aged, Pilot Projects, RNA, Viral, blood, Recombinant Proteins, adverse effects, Ribavirin, adverse effects, Sulfonamides, adverse effects, Sustained Virologic Response, Treatment Failure, Treatment Outcome, Viral Load, drug effects
Référence
Eur J Gastroenterol Hepatol. 2018 03;30(3):302-309